Skip to content

Integra LifeSciences IART Amortization of debt issuance costs and expenses associated with debt refinancing

Amortization of debt issuance costs and expenses associated with debt refinancing at other companies

RBC Bearings logo
RBC BearingsRBC
$0-100%
Genpact logo
GenpactG
$770K+40.0%
Garrett Motion Inc. logo
Garrett Motion Inc.GTX
$1.75M-81.1%
OppFi logo
OppFiOPFI
$605K-41.9%
DoubleVerify Holdings logo
DoubleVerify HoldingsDV
$109K0.0%
ESAB logo
ESABESAB
$5.76M+818%

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B+53.4%
Enterprise value$3.12B+21.1%
P/S0.8×+0.3×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept iart:AmortizationOfDebtIssuanceCostsAndDebtRefinancedFees.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's amortization of debt issuance costs and expenses associated with debt refinancing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's amortization of debt issuance costs and expenses associated with debt refinancing?
Integra LifeSciences (IART) reported amortization of debt issuance costs and expenses associated with debt refinancing of $995K in Q1 2026.
How has Integra LifeSciences's amortization of debt issuance costs and expenses associated with debt refinancing changed year-over-year?
Integra LifeSciences's amortization of debt issuance costs and expenses associated with debt refinancing decreased by 28.2% year-over-year, from $1.39M to $995K.
What is the long-term trend for Integra LifeSciences's amortization of debt issuance costs and expenses associated with debt refinancing?
Over 4 years (2021 to 2025), Integra LifeSciences's amortization of debt issuance costs and expenses associated with debt refinancing has grown at a -5.5% compound annual growth rate (CAGR), from $7.03M to $5.61M.
What does amortization of debt issuance costs and expenses associated with debt refinancing mean?
This represents the non-cash periodic expense recognized to amortize costs incurred during the issuance of debt or refinancing activities. It reflects the systematic allocation of financing-related fees over the life of the debt instrument, impacting net income without affecting cash flow. Investors track this to separate non-cash accounting adjustments from actual cash interest payments.